May 16th 2024
Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.
April 30th 2024
Your daily dose of the clinical news you may have missed.
April 22nd 2024
Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.
April 18th 2024
Your daily dose of the clinical news you may have missed.
April 11th 2024
In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.
2 Commerce Drive
Cranbury, NJ 08512